Recent 8-K filings for VOR

• Mar 27, 2026 23:59 UTC other_material materiality 0.75 positive item 1.01item 3.02item 7.01item 9.01

  Vor Biopharma raises $75M via private placement with TCGX for telitacicept development

  Gross proceeds of $75M from sale of 5.34M shares at $14.05/share to TCGX affiliates.

• Jan 02, 2026 23:59 UTC leadership materiality 0.60 neutral item 5.02item 9.01

  Vor Biopharma Chief Development Officer Qing Zuraw departs Dec 31; gets $565K severance + consulting

  Dr. Qing Zuraw, Chief Development Officer, resigned effective Dec 31, 2025 to pursue other opportunities.

• Dec 18, 2025 23:59 UTC other_material materiality 0.80 neutral item 1.01item 3.02item 5.02item 7.01item 9.01

  Vor Bio raises $150M in private placement; appoints two new directors

  Private placement of 13.9M shares at $10.81 for gross proceeds of ~$150M.

• Dec 09, 2025 23:59 UTC other_material materiality 0.60 neutral item 5.02

  Vor Biopharma reprices employee stock options to $8.18; CEO gets 4.16M options repriced

  Board reduced exercise price of ~5.2M underwater options to $8.18, the Dec 5, 2025 closing price.

• Nov 12, 2025 23:59 UTC other_material materiality 0.70 negative item 8.01item 9.01

  Vor Biopharma announces $100M public offering of 10M shares at $10 each to fund telitacicept development

  10,000,000 shares at $10.00 each; expected net proceeds ~$93.7M (or $107.8M if underwriters' option fully exercised).

• Nov 03, 2025 23:59 UTC leadership materiality 0.70 positive item 5.02item 7.01item 9.01

  Vor Bio appoints Jeremy Sokolove CMO; amends CDO severance terms

  Dr. Jeremy Sokolove appointed CMO effective Nov 3, 2025; has >20 yrs rheumatology/autoimmune R&D experience.

• Oct 28, 2025 23:59 UTC other_material materiality 0.60 neutral item 7.01item 9.01

  Vor Biopharma reports 48-week Phase 3 data for telitacicept in Sjögren's disease from China

  Webcast held Oct 28, 2025 to discuss late-breaking 48-week Phase 3 results from China.

• Aug 27, 2025 23:59 UTC other_material materiality 0.60 neutral item 5.02item 5.07item 8.01item 9.01

  Vor Biopharma stockholders approve reverse stock split, equity plan amendment; files $119.7M ATM prospectus

  Stockholders approved reverse stock split in range 1-for-5 to 1-for-30; board to determine ratio.

• Jul 22, 2025 23:59 UTC leadership materiality 0.65 neutral item 5.02item 7.01item 9.01

  Vor Bio appoints Qing Zuraw as CDO, Michel Detheux and Bo Cumbo as directors

  Resignation of director Sven (Bill) Ante Lundberg effective July 17, 2025; no disagreement cited.

• Jul 10, 2025 23:59 UTC leadership materiality 0.65 positive item 5.02item 7.01item 9.01

  Vor Biopharma appoints Sandesh Mahatme as CFO and Chief Business Officer

  Sandesh Mahatme appointed CFO, Principal Financial Officer and Principal Accounting Officer, effective July 9, 2025.

• Jun 26, 2025 23:59 UTC other_material materiality 0.90 positive item 1.01item 1.02item 3.02item 5.02item 7.01item 9.01

  Vor Bio licenses telitacicept from RemeGen for $125M upfront, raises $175M PIPE, appoints new CEO

  License deal: Vor Bio gets ex-China rights to telitacicept (global Phase 3 for gMG) for $125M upfront ($45M cash + $80M warrants); up to $4B+ milestones plus royalties.

Executive changes

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

4 positive 1 negative 12 neutral

source · VOR on sec.gov